Compare IPSC & BRBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPSC | BRBI |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | 188 |
| Industry | Medicinal Chemicals and Botanical Products | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 295.0M |
| IPO Year | 2021 | 2025 |
| Metric | IPSC | BRBI |
|---|---|---|
| Price | $1.61 | $11.24 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | ★ 386.4K | 834.0 |
| Earning Date | 11-12-2026 | 11-06-2026 |
| Dividend Yield | N/A | ★ 8.67% |
| EPS Growth | ★ 91.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $109,164,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.79 |
| P/E Ratio | ★ N/A | $11.72 |
| Revenue Growth | ★ 1556.76 | N/A |
| 52 Week Low | $0.44 | $9.09 |
| 52 Week High | $2.97 | $16.61 |
| Indicator | IPSC | BRBI |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 54.78 |
| Support Level | $0.90 | $10.90 |
| Resistance Level | $2.39 | $11.97 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.02 | 0.25 |
| Stochastic Oscillator | 11.36 | 94.71 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.